7,228 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Atria Wealth Solutions Inc.

Key Points

• Atria Wealth Solutions Inc. has acquired 7,228 shares of Hims & Hers Health, valued at approximately $356,000, marking a new position for the institutional investor in the second quarter.
• Recent analyst reports indicate a shift in sentiment, with Zacks Research and Wall Street Zen downgrading the stock from "strong-buy" and "buy" ratings to "hold," as Hims & Hers Health faces challenges meeting revenue estimates.
• The company's stock performance showcases significant volatility, with a one-year low of $18.33 and a high of $72.98, alongside a current P/E ratio of 64.25.

Atria Wealth Solutions Inc. acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,228 shares of the company's stock, valued at approximately $356,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Signaturefd LLC lifted its position in Hims & Hers Health by 17.7% during the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after purchasing an additional 388 shares during the period. Lake Hills Wealth Management LLC bought a new stake in Hims & Hers Health during the second quarter worth about $277,000. Occidental Asset Management LLC bought a new stake in Hims & Hers Health during the second quarter worth about $305,000. Dakota Wealth Management bought a new stake in Hims & Hers Health during the second quarter worth about $354,000. Finally, Fiduciary Alliance LLC lifted its position in Hims & Hers Health by 120.4% during the second quarter. Fiduciary Alliance LLC now owns 109,253 shares of the company's stock worth $5,446,000 after purchasing an additional 59,686 shares during the period. Institutional investors own 63.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HIMS. Zacks Research cut shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Wall Street Zen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. UBS Group set a $30.00 target price on shares of Hims & Hers Health in a report on Monday, June 23rd. Finally, Truist Financial dropped their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a report on Monday, August 18th. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $51.40 on Tuesday. The business has a 50 day moving average of $51.04 and a 200-day moving average of $49.21. Hims & Hers Health, Inc. has a 1 year low of $18.33 and a 1 year high of $72.98. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The company has a market capitalization of $11.62 billion, a P/E ratio of 64.25, a P/E/G ratio of 3.39 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same period in the prior year, the company earned $0.06 EPS. The business's quarterly revenue was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $506,060.50. Following the completion of the sale, the insider owned 169,940 shares of the company's stock, valued at approximately $8,581,970. This represents a 5.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Michael Chi sold 900 shares of the stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $58.25, for a total transaction of $52,425.00. Following the sale, the insider directly owned 291,439 shares of the company's stock, valued at $16,976,321.75. This represents a 0.31% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,448,056 shares of company stock worth $75,139,240. 17.71% of the stock is owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.